Showing 4101-4110 of 7767 results for "".
- FDA Clears Candela's Vbeam 595 nm Pulsed Dye Laser for the Treatment of Port Wine Stains and Hemangiomas in the Pediatric Populationhttps://practicaldermatology.com/news/fda-clears-vbeam-595-nm-pulsed-dye-laser-for-the-treatment-of-port-wine-stains-and-hemangiomas-in-the-pediatric-population/2461824/The U.S Food and Drug Administration has cleared candela’s Vbeam family of 595 nm wavelength pulsed dye lasers (PDL) to treat cutaneous capillary malformations, and infantile hemangiomas (IH)/congenital hemangiomas in the pediatric population (from birth – 21 years of age).
- Oro Health, Dermago Unveil Consumer Version of its AI-powered Dermatology Assessment and Recommendation Toolhttps://practicaldermatology.com/news/oro-health-dermago-unveil-consumer-version-of-its-ai-powered-dermatology-assessment-and-recommendation-tool/2461822/Oro Health and Dermago are unveiling the public version of DermSmart, a tool designed to classify skin types and minor skin conditions. This new AI-driven version offers patients the ability to upload pictures of their skin condition, ask questions and interact with the tool i
- Topline Phase 2b Data: Amlitelimab Performs Well in ADhttps://practicaldermatology.com/news/topline-phase-2b-data-amlitelimab-performs-well-in-ad/2461820/Sanofi’s amlitelimab showed statistically significant improvements in signs and symptoms of moderate-to-severe atopic dermatitis in adults, according to topline Phase 2b data. Amlitelimab is a fully human non-depleting monoclonal antibody that binds to OX40-Ligand, a key immune re
- HS Pipeline Update: HS Patients Taking Nanobody Sonelokimab Hit HiSCR 75 as Early as Week 12https://practicaldermatology.com/news/hs-pipeline-update-hs-patients-taking-nanobody-sonelokimab-hit-hiscr-75-as-early-as-week-12/2461806/Nanobody Sonelokimab is looking good in patients with moderate-to-severe hidradenitis suppurativa (HS), according to topline Phase 2 results from MoonLake Immunotherapeutics. Nanobodies are antibody-derived targeted therapies. They consist of one or more domains based on
- Breaking Business News: Lilly to Acquire DICE Therapeuticshttps://practicaldermatology.com/news/breaking-business-news-lilly-to-acquire-dice-therapeutics/2461796/Eli Lilly and Company will acquire DICE Therapeutics, Inc. for a cool $2.4 billion to expand its immunology pipeline. DICE Therapeutics, Inc. is a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic c
- EAACI News: Barzolvolimab May Help Tame Chronic Spontaneous Urticariahttps://practicaldermatology.com/news/eaaci-news-barzolvolimab-may-help-tame-chronic-spontaneous-urticaria/2461786/Celldex Therapeutics, Inc.’s barzolvolimab is looking good in chronic spontaneous urticaria, according to data from the Phase 1b single-dose cholinergic cohort included in the chronic inducible urticaria (CIndU) trial that was presented at the European Academy of Allergy and Clini
- Cutera's AviClear Scores FDA Nod as Long-Term Acne Treatmenthttps://practicaldermatology.com/news/cuteras-aviclear-scores-fda-nod-as-long-term-acne-treatment/2461784/The U.S. Food and Drug Administration (FDA) has cleared AviClear as a long-term treatment for mild to severe inflammatory acne vulgaris. Cutera’s AviClear initially received FDA clearance for treating acne in March 2022. Now, the FDA has cleared the device for the long
- Fall Clinical PAs & NP Update: Castle's DecisionDx-SCC Can Identify Tumors Likely to Spread in Low-Risk CSCChttps://practicaldermatology.com/news/fall-clinical-pas-np-update/2461778/Castle Biosciences, Inc.’s DecisionDx-SCC test can identify tumors likely to metastasize in patients with cutaneous squamous cell carcinoma deemed low risk by traditional staging, according to research presented at the the 2023 Fall Clinical Dermatology Conference for PAs &am
- Engineered Human Tissue May Help Study Mosquito Bites, Diseaseshttps://practicaldermatology.com/news/engineered-human-tissue-may-help-study-mosquito-bites-diseases/2461774/Researchers have created engineered human tissue to study mosquito bites and the diseases they transmit. The team led by College of Medicine biomedical researcher Bradley Jay Willenberg with Mollie Jewett (UCF Burnett School of Biomedical Sciences) and Andrew Dickerson (University of Te
- Highly Trafficked Roads Up AD Risk in Kids, Teenshttps://practicaldermatology.com/news/highly-trafficked-roads-up-ad-risk-in-kids-teens/2461772/Traffic-related air pollution may increase children and teen’s risk for atopic dermatitis report researchers at National Jewish Health in Denver, Colo. For the study, researchers reviewed charts of patients 0-18 years of age who had been seen at National Jewish Health i